Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

South Korean pharmaceutical and biotech companies are on track to exceed 10 trillion won ($7.5 billion) in licensing revenues ...

Pfizer and Arvinas' experimental treatment significantly extends progression-free survival in breast cancer patients with ...

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...